ONCY — Oncolytics Biotech Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Oncolytics Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | USG | USG |
| Status: | fx Final | fx Final | fx Final | Final | Final |
| Net Income/Starting Line | -21 | -19.1 | -20.6 | -22.8 | -28.8 |
| Depreciation | |||||
| Non-Cash Items | 3.45 | 0.535 | -2.12 | 0.301 | 7.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.724 | 0.3 | 1.31 | 2.52 | 1.18 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -17.9 | -17.9 | -21.1 | -19.9 | -20.1 |
| Capital Expenditures | -0.228 | -0.042 | -0.006 | -0.174 | -0.006 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -15.6 | 15 | — | — |
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.228 | -15.7 | 15 | -0.174 | -0.006 |
| Financing Cash Flow Items | 26.3 | 9.66 | 7.6 | 4.98 | 14.1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 26.3 | 9.38 | 23.7 | 5.03 | 14.1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 8.01 | -22.7 | 17.2 | -15.3 | -5.88 |